Five Prime Therapeutics, Inc.

Five Prime Therapeutics, Inc.

Five Prime Therapeutics, Inc.

Overview
Date Founded

2001

Headquarters

TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO, CA, 94080

Type of Company

Public

Employees (Worldwide)

51

Industries

Biotechnology
Hospitals & Patient Services
Pharmaceuticals
Medical Support Services

Company Description

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of novel protein therapeutics. Its product candidates includes, Cabiralizumab (FPA008), Bemarituzumab (FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, C.

Contact Data
Trying to get in touch with decision makers at Five Prime Therapeutics, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Director, President & Chief Executive Officer

Executive Vice President & Chief Financial Officer

Chief Strategy Officer

Executive Vice President & Chief Medical Officer

Senior Vice President, Strategic Technology Operations

Director

Director

Director

Associate Director

Board of Directors

Former Senior Vice President, Business Development, Strategy & Innovation at Pfizer, Inc.

Founder at Kapital Consulting LLC

Founding Fellow at Biotechnology Study Center at New York University School of Medicine

Managing Partner at Hyphen Advisors LLC

Vice Chairman at National Association for Continence

Director, President & Chief Executive Officer at Five Prime Therapeutics, Inc.

Former President & General Manager, Oncology Business Unit at Pfizer, Inc.

Founder at Bay Way Consultants LLC

Paths to Five Prime Therapeutics, Inc.
Potential Connections via
Relationship Science
You
Five Prime Therapeutics, Inc.
Owners & Shareholders
Details Hidden

RA Capital Management, LLC (“RA Capital”) is a crossover fund manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics. The flexibility of its strategy allows RA Capital to lead private, IPO, and follow-on financings for its portfolio companies, both facilitating the crossover process and allowing management teams to drive value creation with minimal capital concerns from inception through commercialization.

Details Hidden

BVF Partners pursues value-oriented investment strategies, investing primarily in the marketable securities issued by biotechnology companies. The firm's investments within the biotechnology sector focus primarily on the securities of companies with market capitalizations of less than $1 billion. BVF may also invest in unregistered securities of public and closely-held private biotechnology companies by directly purchasing from issuers or other shareholders, in privately negotiated transactions, common stock, convertible preferred stock and/or debt instruments with warrants, options and/or similar rights to acquire an equity interest. The firm also pursues a second investment strategy on that invests in equity or equity-linked securities of companies involved in the biotechnology industry and related fields that, as of the time of the acquisition of such securities, have a market capitalization of $350 million to $3 billion.

Details Hidden

Magnetar Financial implements a variety of different strategies in managing private investment funds and separately managed accounts (SMAs) which designed to achieve attractive risk-adjusted rates of return. Some of the funds and SMAs employ a multi-strategy approach, utilizing a wide range of strategies across a range of geographies, while others focus on one or just a few strategies. It may hold both long and short positions in a broad range of securities, derivatives, and other assets. In executing their investment strategies, the funds and SMAs may enter into joint venture or co-investment arrangements, participate in pooled investment vehicles, invest with affiliated or unaffiliated advisors or managers, or make direct investments in operating entities. The firm’s main investment strategies are divided into the following categories: relative-value, event-driven, directional, hybrid and other investment strategies.

Recent Transactions
Details Hidden

Amgen, Inc. purchases Five Prime Therapeutics, Inc.

Details Hidden

Five Prime Therapeutics, Inc. issued . USD Common Stock

Details Hidden

Five Prime Therapeutics, Inc. issued USD Common Stock

Transaction Advisors
Underwriter

Advised onFive Prime Therapeutics, Inc. issued . USD Common Stock

Escrow Agent

Advised onFive Prime Therapeutics, Inc. issued . USD Common Stock

Underwriter

Advised onFive Prime Therapeutics, Inc. issued USD Common Stock

Legal Advisor

Advised onFive Prime Therapeutics, Inc. issued USD Common Stock

Legal Advisor

Advised onFive Prime Therapeutics, Inc. issued . USD Common Stock

Underwriter

Advised onFive Prime Therapeutics, Inc. issued . USD Common Stock

Advisors & Consultants
Legal Advisor

Partner, Palo Alto at Cooley LLP

Legal Advisor

Partner, Palo Alto at Cooley LLP

Legal Advisor

Partner, Palo Alto at Cooley LLP

Clients

Seattle Genetics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in pivotal trial for patients with relapsed or refractory hodgkin lymphoma. The company's other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc. The company was founded in 1998 and is headquartered in Bothell, Washington.

Bristol-Myers Squibb Company Our company has a strong legacy of innovation that began in New York in 1858 when Edward R. Squibb, M.D., founded a pharmaceutical company in Brooklyn, and in 1887 when two friends, William McLaren Bristol and John Ripley Myers purchased a struggling drug manufacturing firm in Clinton. Together, they laid the foundation for our company today — a global BioPharma leader that continues this legacy of innovation.

Zai Lab Ltd. is a biopharmaceutical company. It engages in the discovering, licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need in the fields of oncology, infectious, and autoimmune diseases. The firm's products include Zejula and Optune. The company was founded by Samantha Ying Du and Marietta Wu in April 2014 and is headquartered in Shanghai, China.

Key Stats and Financials As of 2020
Market Capitalization
$1.76B
Total Enterprise Value
$387M
Earnings Per Share
$-2.29
Revenue
$13.2M
Net Profit
$-84.3M
Total Equity
$265M
EBITDAMargin
-534.22%
TEVNet Income
-4.59x
Debt TEV
0.12x
Enterprise Value / Sales
29.35x
Total Debt
$47.4M
EBITDA
$-70.4M
Three Year Compounded Annual Growth Rate Of Revenue
-30.65%
Non-Profit Donations & Grants
Investors
Details Hidden

Founded in 1992, TPG specializes in recognizing value – or the potential for value – where others do not. Our contrarian philosophy, global reach, and deep investment and operational expertise set TPG apart from other firms. Our complementary asset classes offer a unique investment platform. TPG has an extensive global network and long-standing, on-the-ground presence in critical markets. TPG has built a strong international presence with 17 offices in 10 countries. We were one of the first U.S.-based private investment firms to establish significant operations in Asia and Europe, in 1994 and 1995 respectively.

Details Hidden

Versant Ventures is an active manager which invests in healthcare companies located across the globe. The firm follows of companies operating in the fields of biotechnology sector such as biopharmaceutical, medical device, and healthcare services/HCIT companies. It provides financing for all stages of company development.

Details Hidden

Healthcap is an active, long-term manager which invests in pharmaceutical, biotechnology and medical technology companies globally. As a multi-stage fund, the firm provides and participates in financing through all stages of company evolution. Their funds have no geographic restrictions.Healthcap's main investment style is to be lead investor and the firm acts predominantly as an influential minority investor, seeking to invest in the commercialization of innovations in medical science where they believe that the structural changes taking place in the pharmaceutical industry create significant opportunities for knowledgeable investors to achieve high financial returns.The firm partners with investee companies and founders, seeking board representation to assist with strategy formulation in the areas of science, business development and finance. They encourage substantial ownership by entrepreneurs and scientific founders and insist on implementing employee equity ownership programs to attract and reward key personnel.Healthcap's in-house science team evaluates the scientific merits of investment proposals and their in-house transaction team structures the transactions. The firm invests independently or in partnership with other investor groups.

Suppliers
Lonza Group AG Pharmaceuticals | Basel, Che

Lonza Group AG engages in the supply of pharmaceutical, healthcare, and life science products. It operates through the following segments: Pharma & Biotech; Specialty Ingredients; and Corporate. The Pharma & Biotech segment comprises development and manufacture of customized active pharmaceutical ingredients and biopharmaceuticals as well as formulation services and delivery systems. The Specialty Ingredients segment consists of two divisions, consumer health and consumer resources and protection. The Corporate segment includes corporate functions, such as finance and accounting, legal, communication, information technology, and human resources. The company was founded in 1897 and is headquartered in Basel, Switzerland.

Galaxy Biotech LLC Pharmaceuticals | Sunnyvale, CA

Galaxy Biotech LLC is an American private company located in Sunnyvale, CA, that operates as a pharmaceutical company.

Kyowa Kirin Co., Ltd. Hospitals & Patient Services | Tokyo, Japan

Kyowa Kirin Co., Ltd. engages in the manufacture and sale of medical and pharmaceutical products. It handles the research, development, production, and sale of in vitro diagnostic reagents and ethical drugs concerning renal anemia, leukemia, cancer, allergies, and hypertension. It also produces and sells medical and industrial raw materials such as amino acids, nucleic acid-related compounds, and healthcare products. The company was founded by Benzaburo Kato on July 1, 1949 and is headquartered in Tokyo, Japan.

Competitors
Merck & Co., Inc. Pharmaceuticals - Kenilworth, NJ

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Jiangsu Hengrui Medicine Co., Ltd. Pharmaceuticals - Lianyungang, China

Jiangsu Hengrui Medicine Co., Ltd. engages in the research, development, manufacture, and sale of drugs. It specializes in antineoplastic agents, surgical anesthesia drugs, features infusion, contrast agents, and cardiovascular drugs. The firm’s products include tablets, oral solution, and suspension of antineoplastic drugs and narcotic drugs; psychotropic substances; soft capsules; freeze-dried powder injection; powder injection; high-volume injection, including multi-layer co-extruded infusion bag, with anti-tumor drugs; small volume injections, including antineoplastic drugs, psychotropic drugs, and non-final sterilization; biological engineering products such as polyethylene glycol recombinant human granulocyte stimulating factor injection; hard capsules; granules; powder; and film and gel. The company was founded in 1970 and is headquartered in Lianyungang, China.

MacroGenics, Inc. Pharmaceuticals - Rockville, MD

MacroGenics is a leader in the discovery and development of innovative medicinces that utilize our next generation antibody-based technologies. Our team of 150+ dedicated individuals is advancing a pipeline of product candidates to treat patients with cancer and other serious, complex diseases. Our products and platforms have attracted multiple partnerships with leading pharmaceutical companies around the globe. Our innovative product candidates leverage our fully-integrated capabilities around the discovery, development, and production of antibodies and incorporate three proprietary technology platforms: Our Dual-Affinity Re-Targeting (DART™) platform enables us to design candidate therapeutics that target multiple disease-causing cells or redundant disease-associated pathways with a single molecule; Our Fc Optimization platform enhances the natural immune system's ability to mediate killing of cancer cells; and Our Cancer Stem Cell platform provides new approaches to target cancers unresponsive to current therapy.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Five Prime Therapeutics, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Five Prime Therapeutics, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Five Prime Therapeutics, Inc..